Based on the metrics, I would recommend a HOLD on SUNPHARMA. The stock has a decent 12-month return and a strong Sharpe Ratio, indicating a good risk-adjusted performance, but the recent 6-month and 3-month returns suggest a neutral sentiment in the short term.